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Care of patients with a diagnosis of chronic obstructive pulmonary disease: a
cluster randomised controlled trial
Abstract
Objective: To evaluate a partnership model of care for patients with a diagnosis of chronic obstructive
pulmonary disease (COPD). Design, setting and participants: Cluster randomised controlled trial with
blinded outcome assessment of 44 general practices in south-western Sydney comprising 451 people
with a diagnosis of COPD, conducted between 2006 and 2009. Intervention: Participants from intervention
group practices were visited at their home by a registered nurse with specific training in COPD care who
worked with the general practitioner, the patient and other health professionals to develop and implement
an individualised care plan based on best-practice guidelines. Participants from control group practices
received usual care. Main outcome measures: The primary outcome was disease-related quality of life
measured using the St George's Respiratory Questionnaire (SGRQ) at 12-month follow-up. Other
outcomes were overall quality of life, lung function, smoking status, immunisation status, patient
knowledge of COPD, and health service use. Results: Of the 451 participants, 257 (57.8%) were confirmed
as having COPD on post-bronchodilator spirometry. Follow-up was completed for 330 patients (73.2%). At
12 months, there was no statistically significant difference in the mean SGRQ scores between
intervention and control groups (38.7 v 37.6; difference, 1.1; 95% CI, - 1.53-3.74; P =0.41) or in measures
of quality of life, lung function and smoking status. Compared with the control group, in the intervention
group, attendance at pulmonary rehabilitation was more frequent (31.1% v 9.6%; OR, 5.16; 95% CI,
2.40-11.10; P =0.002) and the mean COPD knowledge score was higher (10.5 v 9.8; difference, 0.70; CI,
0.10-1.21; P=0.02). Conclusion: The nurse-GP partnership intervention did not have an impact on diseaserelated quality of life at 12-month follow-up. However, there was evidence of improved quality of care, in
particular, in attendance at pulmonary rehabilitation and patient knowledge of COPD.
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Abstract
Objective: To evaluate a partnership model of care for patients with a diagnosis of
chronic obstructive pulmonary disease (COPD).
Design, setting and participants: Cluster randomised controlled trial with blinded
outcome assessment of 44 general practices in south-western Sydney comprising
451 people with a diagnosis of COPD, conducted between 2006 and 2009.
Intervention: Participants from intervention group practices were visited at their
home by a registered nurse with specific training in COPD care who worked with
the general practitioner, the patient and other health professionals to develop and
implement an individualised care plan based on best-practice guidelines.
Participants from control group practices received usual care.
Main outcome measures: The primary outcome was disease-related quality of life
measured using the St George’s Respiratory Questionnaire (SGRQ) at 12-month
follow-up. Other outcomes were overall quality of life, lung function, smoking
status, immunisation status, patient knowledge of COPD, and health service use.
Results: Of the 451 participants, 257 (57.8%) were confirmed as having COPD on
post-bronchodilator spirometry. Follow-up was completed for 330 patients
(73.2%). At 12 months, there was no statistically significant difference in the mean
SGRQ scores between intervention and control groups (38.7 v 37.6; difference, 1.1;
95% CI,  1.53–3.74; P = 0.41) or in measures of quality of life, lung function and
smoking status. Compared with the control group, in the intervention group,
attendance at pulmonary rehabilitation was more frequent (31.1% v 9.6%; OR, 5.16;
95% CI, 2.40–11.10; P = 0.002) and the mean COPD knowledge score was higher
(10.5 v 9.8; difference, 0.70; CI, 0.10–1.21; P = 0.02).
Conclusion: The nurse–GP partnership intervention did not have an impact on
disease-related quality of life at 12-month follow-up. However, there was evidence
of improved quality of care, in particular, in attendance at pulmonary rehabilitation
and patient knowledge of COPD.
Trial registration: Australian Clinical Trials Registry ACTRN012606000304538.

from hospital on clinical outcomes
in patients with COPD.7 There was
no difference between groups in
health-related quality of life or hospital admissions. Patients in the
in tervention group had hig her
knowledge scores and were more
satisfied with their care. In that
study, less than a third of the genera l prac tition e rs r emem bere d
receiving the care plan, and there
were no differences in GP visits or
management.
We hypothesised that more active
engagement of the GPs, and the
nurse having a role not only in
developing but also implementing a
plan of care, would be more effective. Therefore, this study evaluated
the effectiveness, compared with
usual care, of a nurse with training
in COPD care working in partnership with the patient and their GP
to develop and implement an

individualised care plan based on
clinical practice guidelines.

Methods
Research design

A cluster randomised trial, with randomisation at the level of the practice,
was conducted to avoid contamination
between intervention and control
groups. The study protocol has been
published.8 Recruitment started in
December 2006 and follow-up was
completed in May 2009. Ethics
approval was from University of New
South Wales and Sydney South West
Area Health Service human research
ethics committees.
Recruitment

GPs were recruited from a list of 256
GPs from practices in south-western
Sydney who had previously taken part

Research
in research or who attended continuing medical education activities held
by local Divisions of General Practice.
GPs on the list were approached by
mail, followed by a telephone call
from one of the researchers (N Z or
S V). Inclusion criteria for GPs were
using an electronic prescribing system
and having seen COPD patients in
the past 12 months.
Participating GPs, who were not
aware of their allocation status at the
time of patient recruitment, were
asked to search their electronic records
to identify patients who had been prescribed medications used for COPD
defined as inhaled 2 agonists, inhaled
corticosteroids, ipratropium bromide,
tiotropium, oral theophylline and oral
corticosteroids. Patients were eligible if
they were aged between 40 and 80
years, had been prescribed one or
more of these medications, and had
seen the GP in the previous 12
months. GPs were then asked to manually review the list generated and
identify patients that they considered
to have a diagnosis of COPD, emphysema or chronic bronchitis, including
those that they considered to have
coexisting problems, such as asthma.
GPs were asked to include patients
regardless of how or where the diagnosis had been made, and information
on the diagnostic process was not collected. Patients were excluded if they
did not speak English or had significant cognitive impairment.
Letters were sent from the practice
to eligible patients inviting them to
take part in the study. Two fortnightly
reminders were sent to the nonresponding patients.
Randomisation

A researcher who took no further part
in the study randomised practices to
intervention or control groups, with
allocation concealment. Details of the
randomisation process have been
published previously.8
Intervention

Two nurses, specifically recruited and
trained for this study, worked in partnership with GPs to implement the
intervention. In the service model, the
nurses were external to the practice
and visited patients in their homes.6
The training program for the nurses
involved attendance at a 2-day work-

shop where the following topics were
presented by expert clinicians: pathophysiology of COPD; assessment of
COPD; spirometry; smoking cessation; management of COPD according to Australian and New Zealand
guidelines;3 the role of pulmonary
rehabilitation in the management of
COPD; and the management of exacerbations. The training covered the
principles and practice of motivational
interviewing and self-management
support. Following the training, there
were monthly meetings lasting 1–2
hours between the nurses and members of the study team (N Z and S V),
and feedback from a respiratory physician on the quality of their spirometry (G M). The intervention and its
implementation are described online
at mja.com.au. The intervention was
delivered between 2007 and 2009.
Control

GPs in the control-group practices
were provided with a copy of the
COPD guidelines, and their patients
received usual care, which was
defined as processes normally followed by the GP and the patient
regarding review, pharmacological
therapy and management of COPD.
Outcome measures

The primary outcome measure was
disease-related quality of life, measured using the St George’s Respiratory Questionnaire (SGRQ) at 12
months after recruitment. The SGRQ
is a validated instrument designed to
measure the impact of respiratory diseases (in particular, asthma and
COPD) on an individual’s life.9 The
SGRQ is scored from zero to 100,
where zero indicates best quality of
life and 100, the worst. A change in
score of ⭓ 4 is considered to be clinically significant.9,10
Other outcome measures were
overall quality of life (measured using
the 12-item Short Form Health Survey [SF-12], which is a generic measure of health impairment); lung
function; smoking status; immunisation status for influenza and pneumococcus; attendance at pulmonary
rehabilitation; patient knowledge of
COPD; and health service use. For
those patients with COPD on spirometry, classification of severity was
made using Global Initiative for

Chronic Obstructive Lung Disease
(GOLD) criteria. 2 The patient’s
knowledge of COPD was measured
by a 12-item scale developed for a
previous project.7 This scale asked
patients if they knew the name of
their chest condition, which immunisations were helpful in reducing the
risk of exacerbations, patient actions
that could help control symptoms and
improve quality of life, and symptoms
suggestive of an exacerbation. Correct
answers scored one point and incorrect answers zero points, resulting in a
score out of 12. The scale has face
validity but has not been subjected to
validation testing.
Outcomes, with the exception of
the SGRQ, were measured at three
points in time: recruitment (baseline), 6 months and 12 months after
randomisation. The SGRQ was
measured at baseline and 12 months.
Assessments were conducted at the
participant’s residence or at the GP’s
practice (according to patient preference) by project officers (O H and I H)
who took no part in the intervention
and were blind to group allocation.
Analysis

The analysis was based on intention
to treat. The effect of the intervention
on continuous variables was estimated and tested in SAS, version 9.2
(SAS Institute Inc) using a mixedmodel procedure, in which time and
treatment groups were fixed-effectand subject-nested within practice
clusters, and time points within subjects were random effects. For the
binary outcome variables, a generalised estimating equation method was
separately implemented at each time
point that incorporated practice cluster effect. The analyses for continuous
and binary variables were adjusted for
baseline values.
Given that the measurement of
outcome variables (with the exception
of SGRQ score) was done at baseline,
6 and 12 months, an analysis was
done to examine whether a time and
intervention group interaction was
present. This was found not to be the
case, so baseline and 12-month measures are reported.
Sample size

The sample size calculation was
based on detecting a between-group
MJA 197 (7) · 1 October 2012
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1 Baseline characteristics of groups
Characteristic
Mean age, years (SD)
No. of men (%)

Intervention (n = 234)

Control (n = 217)

65.8 (10.3)

64.4 (10.3)

110 (47.0%)

106 (48.8%)

No. of current smokers (%)

74 (31.6%)

61 (28.1%)

No. with FEV1/FVC < 0.7 (%)

146 (62.4%)

111 (51.2%)

Stage 1

28 (12.0%)

20 (9.2%)

Stage 2

70 (29.9%)

63 (29.0%)

Stage 3

38 (16.2%)

19 (8.8%)

Stage 4

10 (4.3%)

GOLD stage: no. of patients (%)

Mean SGRQ score (SD)

9 (4.1%)

42.0 (18.3)

42.0 (19.4)

Mean COPD knowledge score (SD)

8.9 (1.4)

8.9 (1.5)

No. vaccinated for influenza (%)

156 (66.7%)

155 (71.4%)

No. vaccinated for pneumococcus (%)

137 (58.5%)

123 (56.7%)

Mean no. of comorbidities

3.6 (

4.1 (

Mean SF-12 score (SD)
Physical component

36.4 (11.1)

36.6 (12.5)

Mental component

49.3 (11.7)

49.0 (11.4)

FEV1= = forced expiratory volume in 1 second. FVC = forced vital capacity. SGRQ = St George’s
Respiratory Questionnaire. GOLD = Global Initiative on Obstructive Lung Disease; stages describe
severity of disease from mild (Stage 1) through to severe (Stage 4). COPD = chronic obstructive
pulmonary disease. SF-12 = 12-item Short Form Health Survey.

difference in SGRQ score of ⭓ 4 at 12
months after intervention.9,10 After
adjusting for clustering, the number
per group required to detect this difference with 80% power at the 5%
significance level was estimated to be
200 per group, based on an intracluster coefficient of 0.01 and a resultant
design effect of 1.09 for a cluster size
of 10. Details of the sample size calculation have been published.8

Results
We recruited 56 GPs from 44 practices
in south-west Sydney. The mean age
of the GPs was 52.3 years and 47%
were men. Participating GPs searched
their patient records, identifying 1144
patients who were eligible and invited
to participate. Of these, 451 (39.4%)
patients were recruited and provided
baseline data, 330 (73.2%) of whom

◆

completed the 12-month assessment
(see the flow diagram online at
mja.com.au). Ch aracteristics of
patients completing the 12-month
assessment compared with those lost
to follow-up were: age, 65.3 v 64.7
years; men, 47.3% v 49.6%; spoke
English at home, 79.1% v 79.7%; and
current smokers, 30.2% v 31.1%.
There was a lower rate of confirmed
COPD than expected. Of the 451 participants, 445 (98.7%) were able to
perform baseline spirometry and, of
these, 257 (57.8%) were confirmed to
have COPD.11
Baseline characteristics of participants are shown in Box 1. There was
a higher rate of confirmed COPD,
lower forced expiratory volume in 1
second and fewer comorbidities in
the intervention group, but the
groups did not differ on the SGRQ or
other characteristics.

There were no statistically significant between-group differences in the
primary outcome measure (SGRQ) or
in overall quality of life, respiratory
function or smoking status at 12month follow-up (Box 2). The intracluster correlation for the SGRQ calculated using the mixed-model
procedure was 0.03. In continuing
smokers, there was a trend towards
fewer cigarettes smoked per day in
the intervention group.
In process-of-care outcomes, more
patients in the intervention group
reported having attended a pulmonary rehabilitation program. This difference was statistically significant
(P = 0.002). Data were not collected
on whether they completed the program. There was a higher rate of
patients in the intervention group
reporting being vaccinated for influenza and pneumococcus, but neither
difference was statistically significant.
There was no difference in the frequency of either GP or hospital or
emergency department attendance in
the previous 3 months. The COPD
knowledge score was statistically significantly higher in the intervention
group (P = 0.02) (Box 3).

Discussion
A notable finding was that only 57.8%
of patients identified as having COPD
and being eligible for the study were
confirmed as having the condition
according to spirometric criteria. We
have previously published baseline
analyses of the accuracy of diagnosis
showing that having a spirometer in
the practice was not predictive of
agreement between the clinical and
spirometric diagnoses.11 Older patient
age was associated with correct diagnosis, while higher numbers of

2 Disease-related and overall quality of life, respiratory function and smoking status at 12-month follow-up
Intervention
(n = 234 randomised)*

Control
(n = 217 randomised)*

Difference (95% CI)

P

38.7 (19.0)

37.6 (19.1)

1.1 ( 1.53–3.74 )

0.41

Physical component

36.3 (11.6)

36.7 (13.0)



0.4 ( 2.1–1.3)

0.61

Mental component

51.0 (11.2)

51.5 (11.3)



0.5 ( 2.3–1.2)

0.55

FEV1 post-bronchodilator, percentage of predicted (SD)

72.3% (24.1%)

73.1% (24.4%)



0.8 ( 3.3–1.7)

0.51

No. of current smokers (%)

47/161 (29.2%)

37/168 (22.0%)

15 (8)

18 (11)

Outcome
SGRQ score
SF-12 score

No. of cigarettes per day (SD) (n = 157)

1.3 (0.6–2.5)†

0.52

 3 (

0.05

6.0–0.04)

* Figures are mean (SD) unless stated otherwise stated. † Odds ratio (95% CI). FEV1 = forced expiratory volume in 1 second. SGRQ = St George’s Respiratory
Questionnaire. SF-12 = 12-item Short Form Health Survey.
◆
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3 Process-of-care outcomes at 12-month follow-up
Patient outcome

Intervention*

Control*

Odds ratio (95% CI)

P

No. vaccinated for influenza (%)

131/161 (81.4% )

129/167 (77.2%)

1.88 (0.88–4.02)

0.13

No. vaccinated for pneumococcus (%)

117/161 (72.7%)

103/167 (61.7%)

1.64 (0.93–2.89)

0.09
0.002

No. attended pulmonary rehabilitation program (%)
No. visited general practitioner in preceding 3 months (%)
No. used hospital or emergency department service in
preceding 3 months (%)
COPD knowledge score (SD)

50/161 (31.1%)

16/167 (9.6%)

5.16 (2.40–11.10)

148/160 (92.5%)

150/169 (88.8%)

1.59 (0.70–3.61)

0.27

27/161 (16.8%)

24/169 (14.2%)

1.21 (0.70–2.10)

0.50

10.5 (2.0)

9.8 (1.9)

0.7 (0.1–1.2)†

0.02

COPD = chronic obstructive pulmonary disease. * Denominators in columns are number of patients with valid data at 12-month follow-up.
† Difference (95% CI).

comorbidities were associated with
misdiagnosis.
The study found no between-group
difference in the primary outcome
meas ure (SG RQ ) a nd als o n o
between-group differences in SF-12
score, lung function or smoking rates
at 12-month follow-up. Differences in
lung function would be unlikely to be
apparent within 12 months, so longer
term follow-up would be needed to
show change in this outcome measure.
Smoking cessation is a key priority for
COPD care, and about 30% of participants in the study were smokers.
However, we did not succeed in getting more patients in the intervention
group to quit. Among continuing
smokers, there were fewer cigarettes
smoked in the intervention versus the
control group, but as the mean difference was only three cigarettes per day,
this would be unlikely to produce a
health benefit.
There was greater attendance at a
pulmonary rehabilitation program
by patients in the intervention
group, indicating improved delivery
of evidence-based care. It has been
shown that participation in pulmonary rehabilitation leads to improvements in health-related quality of
life (measured by the SGRQ) at the
end of the program.12 The fact that
these benefits were not apparent in
our study may be due to insufficient
numbers of participants attending
an d/o r co mp le tin g pu lm on a ry
rehabilitation, or due to improvements evident at the end of the
program not being sustained to the
outcome measurements points. The
higher rate of influenza and pneumococcal vaccination in the intervention compared with the control
group suggests improved delivery
of care, but these differences were
not statistically significant. Patients
in the intervention group had

higher COPD knowledge scores,
presumably related to the educat io n p rov ide d by th e n u rs e s,
although the clinical importance of
this is uncertain.
Our study had some limitations.
The participating practices were
drawn from a list of practices that had
previous involvement in research or
teaching, or that had attended continuing educational events. Therefore,
they may not have been entirely representative of all practices in Australia. Sources of potential bias are
that the uptake of the invitation to
participate was 39.4%, and that 26.8%
of participants randomised were lost
to follow-up at 12 months.
The criterion for entry into the
study was having a diagnosis of
COPD and we did not require this to
be confirmed on spirometry. This
reflects the real-world situation in primary care, where the diagnosis is
often made and treatment initiated on
clinical grounds.13-15 The rate of misclassification was similar to that of
other studies from Australia16 and
internationally.17,18
However, the intervention components were based on evidence of
effectiveness from studies in patients
with COPD confirmed on spirometry,
and the intervention may only have
been effective in this subgroup of participants. A subgroup analysis, which
examined the outcomes for the 257
patients who had COPD confirmed
on spirometry, was similar to the
intention-to-treat analysis, with no
statistically significant differences at
12 months in SGRQ, SF-12, lung
function or smoking rates. As the
numbers were smaller, there was a
risk of a type 2 error, and this risk was
further increased as the intracluster
correlation found for the SGRQ (0.03)
was slightly higher than our estimate
of 0.01.18

◆

Our findings are consistent with
the current uncertainty about the
effect of disease-management programs, including self-management
support, for COPD. While some studies have shown benefit,6,19 others,
including a recently published study
of comprehensive care management
to prevent COPD hospitalisations,
have had negative results.20
The lack of impact from the intervention on prevalence of smoking
demonstrates the need to continue to
develop and test interventions to
encourage smoking cessation in people
with COPD. There is continuing
debate about whether performing
spirometry and informing patients of
abnormal results increases smoking
cessation.21,22 There has been promising research on the use of lung age as
a tool to encourage quitting, but this
has not been studied in patients with
COPD.23 The evidence base on smoking-cessation interventions for people
with COPD is very limited,24 and
there is a need for studies that evaluate both psychosocial approaches and
innovative ways of using pharmacotherapy.25
Pulmonary rehabilitation has the
potential to improve health-related
quality of life, but even in the intervention group, less than a third of
patients attended pulmonary rehabilitation. This was consistent with previous research reporting uptake of
33%–39% in pulmonary rehabilitation
programs provided in outpatient clinics.26 There is evidence that homebased programs may be as effective as
supervised hospital outpatient-based
programs,27,28 but studies on implementation are lacking. Finally, there is
the question of whether the nurse–GP
partnership intervention to implement evidence-based care would have
been effective if it had been implemented with patients at an early stage
MJA 197 (7) · 1 October 2012
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of the disease. It has been suggested,
for example, that the benefit of smoking cessation may be greatest in
asymptomatic patients with measureable lung function impairment.29
The intervention tested in this
study showed promise in that there
were improvements in process of care,
but it did not have a measurable
impact on disease-related quality of
life, respiratory function or smoking
status. Given the burden that COPD
places on individuals and society, and
the importance of improved care in
the community, further research to
identify effective intervention s,
including examination of their costeffectiveness, is needed. This could
involve more intensive interventions
to support smoking cessation, new
ways of delivering pulmonary rehabilitation, and intervention soon after
diagnosis of COPD.
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What is a QR code?
You may have noticed a strange symbol like the one here on some pages of the Journal (see pages 383 and 403) or in other
places, such as on bus-stop ads or at the counter at cafes. These are called quick response (QR) codes, which work
similarly to barcodes, in that they can digitally encode a range of information. They can be scanned by your tablet or
smartphone and, in the Journal, they will take you directly to multimedia content such as podcasts without you having to
type in a web address. The one on this page will take you to the MJA homepage.
How do I scan QR codes?

You need a tablet or smartphone and a QR reader to scan QR codes.
1) First download a free app that will scan QR codes. Go to the appropriate source of apps for your device (eg, Android
Market, the App Store or Google Play) and download a free QR code reader such as i-nigma, RedLaser or Barcode
Scanner.
2) Install the scanner app to your device.
3) With the scanner app open, hold your tablet or smartphone over the QR code.
QR codes in the MJA

You may see QR codes in the margins of MJA articles or in some advertising, which indicates that there is more
information or multimedia content such as a podcast or video associated with that article. When you scan the QR code,
your device will be taken to the website for that extra content, so that you can read, download or live stream the content.
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Flow diagram for the chronic obstructive pulmonary disease study, December 2006 – May 2009
Assessed for eligibility:
261 GPs from 160 practices
5 GPs consented but dropped out
before patient invitation

200 GPs excluded/refused
to participate

1144 patients of 56 GPs from 44 practices
assessed for eligibility and invited

517 patients provided written consent

66 losses before randomisation:
48 dropped out
14 lost contact
4 died

GP practices randomised: 44 clusters
Baseline data obtained: 451 patients

Allocated to intervention
26 GPs in 22 clusters
(all clusters received allocated intervention)
234 patients consented and allocated
52 did not receive intervention
(Mean cluster size, 10.6 patients; median,
8.0 patients; range, 1–38 patients)

Allocated to control
30 GPs in 22 clusters allocated
(all clusters received allocated intervention)
217 patients consented and allocated
All patients received intervention
(Mean cluster size, 9.9 patients; median,
6.5 patients; range 2–29 patients)

Lost to follow-up
73 patients from 14 clusters
2 clusters dropped out
39 patients dropped out
20 patients lost to follow-up
14 patients died

Lost to follow-up
48 patients from 19 clusters
No clusters dropped out
26 patients dropped out
13 patients lost to follow-up
9 patients died

Analysed at 12-month follow-up
20 clusters analysed
161 patients analysed
(Mean cluster size, 8.1 patients; median,
7.0 patients; range, 1–25 patients)

Analysed at 12-month follow-up
22 clusters analysed
169 patients analysed
(Mean cluster size, 7.7 patients; median,
6.0 patients; range, 1–27 patients)
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Box unedited, as supplied by the authors
Intervention description
Two intervention nurses with specific training worked in partnership with GPs, patients
and other care providers over a six month period. Behaviour change was encouraged
through use of motivational interviewing. Self management support was provided in
the form of assistance with goal setting and action planning.
The intervention comprised

400

•

An initial home visit involving comprehensive assessment, including pre and post
bronchodilator spirometry.

•

Development of a personalised care plan based on the recommendations of the
COPDX guidelines using an electronic template provided. The care plan was based
on the nurse assessment and discussion with the patient of goal setting and action
planning. It the contained relevant components of smoking cessation, influenza and
pneumococcal immunisation, pulmonary rehabilitation, medication review,
nutrition, psychosocial issues, patient education, comorbidities and complications
of COPD. Where spirometry did not confirm COPD the nurse discussed with the GP
the actions following this and what parts of the care plan applied to these patients.

•

The nurse worked with the patient, their GP and other health professionals to
implement the plan. This involved at least two home visits and five telephone
contacts from the nurse and a minimum of two consultations with their GP. The
nurse facilitated referral and teamwork with other services as needed such as
smoking cessation program, pulmonary rehabilitation program, pharmacist,
specialist physician, Action Plans for exacerbations were discussed and patients
were encouraged to take these to their GPs for completion.

•

At the end of the six month intervention period progress against the goals in the plan
were noted and a copy of the plan with these annotations provided to the GP. The
completion of the plan was used to define that the patient had received the
intervention.
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